Table 3.
IBD in Ankylosing Spondylitis.
| Study, Year | Number of Patients, Sex, Age | Treatment | Interval from Anti-TNF Onset to IBD Onset | IBD | Outcome |
|---|---|---|---|---|---|
| Calin et al., 2004 [27] | 2 n/a | ETN | 8.1 months | 1 CD 1 UC |
n/a |
| Braun et al., 2007 [24] | 18 F + M | 14 ETN | n/a | 8 CD 6 UC |
n/a |
| 1IFX | 1 CD | ||||
| 3 ADA | 1CD 2UC |
||||
| O’Toole et al., 2016 [14] | 14 F + M | 14 ETN | n/a | 11 CD 3 UC |
n/a |
| Toussirot et al., 2012 [3] | 5 F, 7 M Mean age: 42.5 |
10 ETN 2 IFX |
n/a | 5 CD 6 CLD 1 ind colitis |
All switch to another anti-TNF, all favorable evolution |
| Song et al., 2008 [26] | 3 F + M | 3 ETN | 11 months; 12 months; 26 months |
3 CD | 2 controlled with SSZ and CS; One with IFX 2 patients—no flares 1 patient re-exposed to ETN—flare 6 months later |
| Fouache et al., 2009 [2] | 3 F, 1 M Mean age: 38 |
3 ETN 1 IFX |
17 months | IBD n/a | Anti-TNF stopped |
| Uskudar et al., 2019 [25] | 7 F + M Mean age: 41.9 ± 11.6 |
3 ETN 3 IFX 1 ADA |
n/a | 7 CD | Switch: 4 ADA 1 CZP 1 IFX + AZA 1 ETN + AZA |
| Jethwa et al., 2013 [28] | 1 M, 45 years | ETN | 6 months | CD | Switch to ADA, no flare |
| Haraoui et al., 2009 [29] | 1 M, 26 years | ETN | 16 months | CD | IFX + MTX, favorable evolution |
| Brandt et al., 2004 [30] | 1 F, 46 years | ETN | 21 weeks | CD | CS + Mesalazine, Favorable evolution |
| Davis et al., 2003 [23] | 1 n/a | ETN | n/a | CD | n/a |
| Yazisis et al., 2008 [31] | 1 M, 23 years | ETN | 6 months | CD | CS + SSZ, favorable evolution |
| Elkayam et al., 2008 [32] | 1 M, 33 years | IFX | 22 months | CD | IFX continued + Mesalazine, favorable evolution |
| Baraliakos et al., 2005 [33] | 1 F, 28 years | ETN | n/a | CD | ETN discontinued CS + Mesalazine Favorable evolution |
| Tsochatzis et al., 2007 [34] | 1 M, 36 years | IFX | 6 months | CD | n/a |
| Mrabet et al., 2012 [35] | 1 M, 27 years | ETN | 11 months | CD | IFX Favorable evolution |
| Tolu S et al., 2018 [36] | 1 M, 29 years | ETN | 10 years | CD | ADA Favorable evolution |
| Hutchings et al., 2019 [4] | 1 M, 49 years | ETN | 8.2 years | CD | ADA + Mesalamine Favorable evolution |
| Marzo-Ortega et al., 2001 [37] | 1 M, 27 years 1 M, 26 years |
ETN ETN |
10 weeks | CD flare CD flare |
n/a |
| Prescott et al., 2007 [16] | 1 M | ETN | 3-4 weeks | UC flare | ETN discontinued CS Favorable evolution |
| Bawany et al., 2014 [38] | 1 M, 25 years | GOL | 3 months | UC flare | GOL discontinued Mesalamine Switch to ADA Favorable evolution |
| Fiehn et al., 2011 [39] | 1 F, 47 years 1 F, 43 years 1 M, 72 years |
3 GOL | 5 months 5 months 2 months |
2 CD flare 1 UC flare |
3 GOL discontinued CS 1 switch to ADA Favorable evolution |
F = female, M = male, IBD = Inflammatory Bowel Disease, UC = ulcerative colitis, CD = Crohn’s disease, CLD = Crohn’s-like disease, ind = indetermined, IFX = Infliximab, ETN = Etanercept, ADA = Adalimumab, GOL = Golimumab, CZP = Certolizumab pegol, n/a = not available, CS = corticosteroids, TNF-α = tumor necrosis factor alpha, 5-ASA = 5-aminosalicylates, SSZ = Sulfasalazine, AZA = Azathioprine, MTX = Methotrexate.